Compare Marvell Technology Inc (MRVL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Sanofi SA — how do they compare? Marvell Technology Inc trades at $232.05 (market cap $200.91B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| MRVL | SNY | |
|---|---|---|
Market Cap | $200.91B | $104.06B |
Sector | Technology | Health |
52-Week High | $316.43 | $52.34 |
52-Week Low | $66.59 | $41.33 |
Enterprise Value | $202.26B | $124.09B |
Dividend Yield | 0.11% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth projections, with management forecasting $12 billion for fiscal 2026 and $18 billion for 2027. Despite negative net income in recent periods, the company has consistently beaten EPS expectations and maintains strong profitability margins. Technical indicators show bullish moving averages with support at $221 and resistance at $231.
Marvell presents significant growth potential driven by AI chip demand, with an 82% analyst buy rating and $303 consensus price target representing 34% upside. Key risks include intense competition from Broadcom, customer concentration, and high valuation multiples. The October Investor Day could serve as a catalyst for further price appreciation if growth projections are reaffirmed.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
